한빛사 논문
Mikyung Kanga, Jihye Honga, Mungyo Jungb, Sung Pil Kwonb, Seuk Young Songb, Han Young Kimb, Ju‐Ro Leeb, Seokyung Kangb, Jin Hanb, Ja‐Hyun Kooc,d, Ju Hee Ryue, Songhyun Limb, Hee Su Sohnb, Je‐Min Choic,d,f, Junsang Dohg, Byung‐Soo Kima,b,h,*
aInterdisciplinary Program for Bioengineering, Seoul National University, Seoul 08826, Republic of Korea
bSchool of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea
cDepartment of Life Science, College of Natural Sciences, Hanyang University, Seoul 04763, Republic of Korea
dResearch Institute for Natural Sciences, Hanyang University, Seoul 04763, Republic of Korea
eCenter for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea
fResearch Institute for Convergence of Basic Sciences, Hanyang University, Seoul 04763, Republic of Korea
gDepartment of Materials Science and Engineering, Seoul National University, Seoul 08826, Republic of Korea
hInstitute of Chemical Processes, Institute of Engineering Research, BioMAX, Seoul National University, Seoul 08826, Republic of Korea
*To whom correspondence should be addressed.
Abstract
Cancer immunotherapies, including adoptive T cell transfer and immune checkpoint blockades, have recently shown considerable success in cancer treatment. Nevertheless, transferred T cells often become exhausted because of the immunosuppressive tumor microenvironment. Immune checkpoint blockades, in contrast, can reinvigorate the exhausted T cells; however, the therapeutic efficacy is modest in 70–80% of patients. To address some of the challenges faced by the current cancer treatments, here T‐cell‐membrane‐coated nanoparticles (TCMNPs) are developed for cancer immunotherapy. Similar to cytotoxic T cells, TCMNPs can be targeted at tumors via T‐cell‐membrane‐originated proteins and kill cancer cells by releasing anticancer molecules and inducing Fas‐ligand‐mediated apoptosis. Unlike cytotoxic T cells, TCMNPs are resistant to immunosuppressive molecules (e.g., transforming growth factor‐β1 (TGF‐β1)) and programmed death‐ligand 1 (PD‐L1) of cancer cells by scavenging TGF‐β1 and PD‐L1. Indeed, TCMNPs exhibit higher therapeutic efficacy than an immune checkpoint blockade in melanoma treatment. Furthermore, the anti‐tumoral actions of TCMNPs are also demonstrated in the treatment of lung cancer in an antigen‐nonspecific manner. Taken together, TCMNPs have a potential to improve the current cancer immunotherapy.
논문정보
관련 링크
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기